Evidence map›Paper›PMID 24764650›Full record

ReviewWorld journal of gastroenterology2014

Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Ali Raza, Gagan K Sood

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05178303 (Composition for Treating Cirrhosis and Liver Cancer), which is not on this map. Cited by 242 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05178303 phase4completednot on this mapstarted 2015, after this paper: background citation

Composition for Treating Cirrhosis and Liver Cancer

TypeinterventionalSponsorNguyen Thi Trieu, MDRan2015 to 2021Enrolled134ConditionsCirrhosis of the LiverArmsSB-1121(1), SB-1121(2)
3 · Its place in the literature

Who cites it

242 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. 3D Printed Biosponge Adsorbers for Capturing Toxic Chemotherapy DrugsACS biomaterials science & engineering · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

182 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ali RazaAli Raza, Department of Internal Medicine, St. Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX 77030, United States.
Gagan K SoodAli Raza, Department of Internal Medicine, St. Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX 77030, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Multiple treatment options are available for HCC including curative resection, liver transplantation, radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agent like sorafenib. The treatment of HCC depends on the tumor stage, patient performance status and liver function reserve and requires a multidisciplinary approach. In the past few years with significant advances in surgical treatments and locoregional therapies, the short-term survival of HCC has improved but the recurrent disease remains a big problem. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. For patients with advanced disease, sorafenib is the only approved therapy, but novel systemic molecular targeted agents and their combinations are emerging. This article provides an overview of treatment of early and advanced stage HCC based on our extensive review of relevant literature.

Indexed as

Carcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticClinical Trials as TopicCombined Modality TherapyEvidence-Based MedicineHumansLiver NeoplasmsLiver TransplantationMolecular Targeted TherapyNiacinamidePhenylurea CompoundsSignal TransductionSorafenibTreatment OutcomeNiacinamidePhenylurea CompoundsSorafenibChemotherapyDrug-eluting beadsHepatocellular carcinomaLiver transplantationRadioembolizationRadiofrequency ablationSorafenibTrans-arterial chemoembolization

Identifiers

PMID24764650
PMCPMC3989948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.